Peptides for Dachshund intervertebral disc disease (ivdd)
The short answer
Dachshunds carry an elevated predisposition to intervertebral disc disease (ivdd). The compounds investigated for it are BPC-157, TB-500. At a typical Dachshund weight of 4–15 kg (9–33 lb), this breed falls in the small / toy breed dosing class.
Intervertebral disc disease (IVDD) in Dachshunds
IVDD occurs when the cushioning disc between vertebrae degenerates and its material displaces into the spinal canal, compressing the cord. In chondrodystrophic breeds — Dachshunds above all — disc degeneration begins in early adulthood, and a herniation can happen during entirely ordinary activity. Presentation ranges from a reluctance to jump to acute paralysis, and severe cases are surgical emergencies where time to decompression drives the outcome. Research interest in peptides here focuses on the recovery period and inflammatory management around the injured cord, always as an adjunct to proper neurological assessment rather than a substitute for it.
Dosing at Dachshund body weight
Calculated for a 10 kg (22 lb) dog — the midpoint of the typical range for this breed.
| Compound | Dose at 10 kg | Frequency | Evidence |
|---|---|---|---|
| BPC-157 | 20–100 mcg | Once daily | Emerging evidence |
| TB-500 | 1–2.5 mg | Loading 1-2x weekly, then half dose weekly | Emerging evidence |
Weigh your dog rather than using a breed average — an individual Dachshund can sit well outside the typical range. Use the dose calculator for an exact figure.
Common questions
What peptides are used for intervertebral disc disease (ivdd) in Dachshunds?+
BPC-157, TB-500 are investigated for intervertebral disc disease (ivdd). No breed-specific pharmacological restriction is established for Dachshunds among these compounds.
How much should a Dachshund be given?+
Dachshunds typically weigh 4–15 kg (9–33 lb), placing them in the small / toy breed class. BPC-157: approximately 20–100 mcg at 10 kg. TB-500: approximately 1–2.5 mg at 10 kg. Weigh your dog rather than relying on a breed average.
Are Dachshunds more prone to intervertebral disc disease (ivdd)?+
Yes. Dachshunds carry an elevated predisposition to intervertebral disc disease (ivdd). Degeneration and herniation of spinal discs causing pain, weakness, or paralysis — a defining risk in chondrodystrophic breeds.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 8.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 9.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 10.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
Other conditions Dachshunds are predisposed to: Osteoarthritis.
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.